Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.
Read More
1 minute read

Johnson & Johnson Unit Janssen Announced New VOYAGER PAD Analysis Confirms Consistent Benefit Of XARELTO Plus Aspirin Following Lower Extremity Revascularization

By Charles Gross
Today, 10:35 AM
The Janssen Pharmaceutical Companies of Johnson & Johnson today announced data from a new prespecified analysis from the Phase 3 VOYAGER PAD clinical trial reinforcing the benefits of the XARELTO® (rivaroxaban) vascular dose (2.5 mg twice daily plus aspirin 100 mg once daily) over standard of care (aspirin alone), demonstrating consistent benefit at 30 days, 90 days and up to three years following

JNJ

Read More
1 minute read

Abbott Labs Announced New Five-year Data Presented At American College Of Cardiology Scientific Sessions And Simultaneously Published In The New England Journal Of Medicine Reinforce The Long-term Safety And Effectiveness Of Mitraclip For Treating Seco…

By Charles Gross
Today, 10:35 AM
Abbott (NYSE: ABT) today announced late-breaking data for MitraClip™, the leading therapy to treat leaky valves in people with mitral regurgitation (MR), that demonstrate long-term benefits of the device in patients battling heart failure.

ABT

Read More
1 minute read

Amarin Announced New REDUCE-IT Data Showing Benefit Of VASCEPA/VAZKEPA In High-Risk Patients With A Recent Acute Coronary Syndrome Event

By Charles Gross
Today, 10:35 AM
Amarin Corporation plc (NASDAQ: AMRN) today announced a new analysis from the VASCEPA/VAZKEPA (icosapent ethyl) cardiovascular outcomes REDUCE-IT study showing the effectiveness of VASCEPA®/VAZKEPA® in patients with recent acute coronary syndrome (<12 months before randomization).

AMRN

Read More
1 minute read

89bio Data Showed Pegozafermin Treatment Was Found To Be Effective In Reducing Triglycerides And Other Atherogenic Lipids In Patients With SHTG, Regardless Of Their Background Lipid-modifying Therapy

By Charles Gross
Today, 10:35 AM
89bio, Inc. (Nasdaq: ETNB) today announced the presentation of additional data from the Phase 2 ENTRIGUE trial of pegozafermin in patients with severe hypertriglyceridemia (SHTG) at the American College of Cardiology's 72nd Annual Scientific Session & Expo Together with World Congress of Cardiology (ACC.23/WCC).

ETNB